Literature DB >> 2184009

Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

J M Henwood1, R N Brogden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2184009     DOI： 10.2165/00003495-199039030-00008

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  336 in total

1.  Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience.

Authors:  P J Walther; S D Williams; M Troner; F A Greco; R Birch; L H Einhorn
Journal:  Cancer Treat Rep       Date:  1986-11

2.  New combination chemotherapy for relapsed acute myeloid leukaemia.

Authors:  A M Worsley; D Catovsky; J M Goldman; D A Galton
Journal:  Lancet       Date:  1984-06-02       Impact factor: 79.321

3.  Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

Authors:  G Perez Manga; P Madrigal Alonso; H Alburquerque Carbuccia
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase II study of etoposide in the treatment of esophageal carcinoma.

Authors:  C J Coonley; M Bains; R Heelan; M Dukeman; D P Kelsen
Journal:  Cancer Treat Rep       Date:  1983-04

5.  Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.

Authors:  N Schmitz; W Gassmann; M Rister; W Johannson; M Suttorp; F Brix; J J Holthuis; W Heit; B Hertenstein; J Schaub
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

6.  Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer.

Authors:  M B McIllmurray; R J Bibby; B E Taylor; L P Ormerod; J R Edge; R J Wolstenholme; R F Willey; J F O'Reilly; N Horsfield; C E Johnson
Journal:  Thorax       Date:  1989-03       Impact factor: 9.139

7.  Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

Authors:  U Tirelli; M D'Incalci; R Canetta; S Tumolo; G Franchin; A Veronesi; E Galligioni; M G Trovò; C Rossi; E Grigoletto
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

8.  Possible enhancement of vincristine neuropathy by VP-16.

Authors:  M Thant; R J Hawley; M T Smith; M H Cohen; J D Minna; P A Bunn; D C Ihde; W West; M J Matthews
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

9.  Improvement of long-term survival in extensive small-cell lung cancer.

Authors:  D V Jackson; L D Case; P J Zekan; B L Powell; R D Caldwell; J D Bearden; E C Nelson; H B Muss; M R Cooper; F Richards
Journal:  J Clin Oncol       Date:  1988-07       Impact factor: 44.544

10.  Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.

Authors:  T Colombo; M Broggini; M Vaghi; G Amato; E Erba; M D'Incalci
Journal:  Eur J Cancer Clin Oncol       Date:  1986-02
View more
  36 in total

1.  Etoposide induces heritable chromosomal aberrations and aneuploidy during male meiosis in the mouse.

Authors:  F Marchetti; J B Bishop; X Lowe; W M Generoso; J Hozier; A J Wyrobek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 2.  Etoposide phosphate, the water soluble prodrug of etoposide.

Authors:  A H Witterland; C H Koks; J H Beijnen
Journal:  Pharm World Sci       Date:  1996-10

Review 3.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

4.  A limited sampling method for estimation of the etoposide area under the curve.

Authors:  A S Strömgren; B T Sørensen; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

6.  Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.

Authors:  S Pashko; D H Johnson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

7.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

8.  Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.

Authors:  Irene Slavc; Elisabeth Schuller; Jutta Falger; Mehmet Günes; Konrad Pillwein; Thomas Czech; Wolfgang Dietrich; Karl Rössler; Karin Dieckmann; Daniela Prayer; Johannes Hainfellner
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

Review 9.  Chemotherapy individualization.

Authors:  Gareth J Veal; Sally A Coulthard; Alan V Boddy
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

Review 10.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.